Alpine Immune Sciences unveils fresh Acazicolcept study results for Systemic Lupus Erythematosus at 2023 Rheumatology Convergence by American College.

The phase 1 trial of LY3410738, a covalent mutant IDH inhibitor, in advanced IDH-mutant CCAs and other tumors was presented at the AACR Congress, paving the way for further outcome evaluation.

NImmune Biopharma unveiled promising early human trial results for NIM-1324, a Phase 2 drug candidate for Systemic Lupus Erythematosus, at the 2023 American College of Rheumatology Convergence.

This article summarized the latest R&D progress of Vincamine, the Mechanism of Action for Vincamine, and the drug target R&D trends for Vincamine.

Novo Nordisk presents cardiovascular results for Wegovy® (Semaglutide 2.4 mg) at the American Heart Association's scientific conference, also concurrently published in the New England Journal of Medicine.

The latest clinical findings of Ianalumab were unveiled at the 2023 AACR Congress, demonstrating its potential effect and setting the stage for subsequent investigations.

Ionis Pharmaceuticals reported successful recruitment completion and encouraging early outcomes from the first phase of the HALOS Phase 1/2a trial for ION582 (BIIB121) targeting Angelman syndrome.

This article summarized the latest R&D progress of Xylometazoline Hydrochloride, the Mechanism of Action for Xylometazoline Hydrochloride, and the drug target R&D trends for Xylometazoline Hydrochloride.

Initial Participant Receives Treatment in Phase III ProstACT GLOBAL Trial for Antibody-driven Prostate Cancer Candidate Therapy, TLX591.

On 14 Apr 2023, the clinical trial evaluating exarafenib (KIN-2787) in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma was reported at the AACR Congress.

Alnylam reports encouraging findings from the KARDIA-1 Phase 2 trial of Zilebesiran, a potential RNAi treatment, designed for addressing hypertension in individuals with significant cardiovascular risk.

This article summarized the latest R&D progress of Zimberelimab, the Mechanism of Action for Zimberelimab, and the drug target R&D trends for Zimberelimab.